California Allergy and Asthma Medical Group

Recent papers from California Allergy and Asthma Medical Group

1. Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthmaBritish Journal of Clinical Pharmacology · 2026
2. Population-Based Incidence of Acute and Chronic Urticaria in Southern California: 2017–2022The Permanente Journal · 2025
3. “I wish someone said along the way”: Patient perspectives on penicillin allergy evaluation during pregnancyAnnals of Allergy Asthma & Immunology · 2025
4. Lung Deposition of Extrafine Versus Nonextrafine Aerosols at Low Inhalation Flow Rates in Adult Asthma Patients: A Composition StudyJournal of Aerosol Medicine and Pulmonary Drug Delivery · 2025
5. Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male VolunteersClinical Pharmacology in Drug Development · 2025
6. The utility of shared decision making in the management of hereditary angioedemaAllergy and Asthma Proceedings · 2024
7. On-treatment clinical remission of severe asthma with real-world longer-term biologic useJournal of Allergy and Clinical Immunology Global · 2024
8. Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE StudyJournal of Asthma and Allergy · 2024
9. 729 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitisBritish Journal of Dermatology · 2024
10. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine · 2023
11. Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi ApproachCurrent Allergy and Asthma Reports · 2023
12. A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitisFrontiers in Allergy · 2023
13. Real-world severe asthma biologic administration and adherence differs by biologicAnnals of Allergy Asthma & Immunology · 2023
14. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthmaAnnals of Allergy Asthma & Immunology · 2023
15. Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE studyEuropean Respiratory Journal · 2022
16. Biologic use and outcomes among adults with severe asthma treated by US subspecialistsAnnals of Allergy Asthma & Immunology · 2022
17. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsThe Journal of Allergy and Clinical Immunology In Practice · 2021
18. Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directionsExpert Opinion on Drug Safety · 2021
19. Safety of ciclesonide in children with asthma: A review of randomized controlled trialsAllergy and Asthma Proceedings · 2021
20. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic ImplicationsAdvances in Therapy · 2021